 This is a Phase 1b, open label, multi-center study of CMB305 sequentially administered LV305 a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene and G305 NY-ESO-1 recombinant protein plus GLA-SE in patients with melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1. 